About the Authors
- Andrew N. Phillips
-
* E-mail: andrew.phillips@ucl.ac.uk
Affiliation Research Department of Infection & Population Health, University College London, London, United Kingdom
- Valentina Cambiano
-
Affiliation Research Department of Infection & Population Health, University College London, London, United Kingdom
- Fumiyo Nakagawa
-
Affiliation Research Department of Infection & Population Health, University College London, London, United Kingdom
- Deborah Ford
-
Affiliation Institute of Clinical Trials and Methodology, University College London, London, United Kingdom
- Jens D. Lundgren
-
Affiliation CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
- Edith Roset-Bahmanyar
-
Current address: Novartis Foundation for Sustainable Development, Basel, Switzerland
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
- François Roman
-
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
- Thierry Van Effelterre
-
Affiliation GlaxoSmithKline Vaccines, Wavre, Belgium
Competing Interests
FR and TV are employees of GlaxoSmithKline group of companies (GSK). FR and TV declare ownership of GSK stock options. AP, VC, FN, DF and JL have no relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc., with GSK. The above-described involvement of GSK does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AP VC FN DF JL ER FR TV. Performed the experiments: AP VC FN. Analyzed the data: AP VC FN DF. Contributed to the writing of the manuscript: AP VC FN DF JL ER FR TV. Had input into developing the model and its programming: AP VC FN DF. Provided clinical input into the model: JL. Gave input in the conception and design of the model as applied to the impact of vaccines, including on assumptions used for the vaccine and vaccination: FR ER TV. Wrote the first draft of the manuscript: AP. Had substantive input into interpretation of results and manuscript editing and refining of text for important intellectual content: AP VC FN DF JL ER FR TV. Approved the final version: AP VC FN DF JL ER FR TV.